|1.||Colombier, M-L: 1 article (12/2006)|
|2.||Saffar, J-L: 1 article (12/2006)|
|3.||Lallam-Laroye, C: 1 article (12/2006)|
|4.||Baroukh, B: 1 article (12/2006)|
|5.||Escartin, Q: 1 article (12/2006)|
|6.||Zlowodzki, A-S: 1 article (12/2006)|
|7.||Barritault, D: 1 article (12/2006)|
|8.||Caruelle, J-P: 1 article (12/2006)|
|9.||Saffar, Jean-Louis: 1 article (02/2004)|
|10.||Barritault, Denis: 1 article (02/2004)|
02/01/2004 - "RG1503 given with cancer treatment might protect patients from mucositis."
02/01/2004 - "These data indicate that mucositis lesions are related to massive release of proteolytic enzymes and are improved by RG1503 treatment, this effect being ascribable in part to restoration of the MMP-TIMP balance. "
02/01/2004 - "In this study, mucositis induced in hamsters by 5-fluorouracil (5-FU) was observed after cheek-pouch scarifications, with and without administration of RGTA (RG1503), a polymer engineered to mimic the protective effects of heparan sulfate. "
|5.||Body Weight (Weight, Body)
|1.||Heparitin Sulfate (Heparan Sulfate)
|5.||Tissue Inhibitor of Metalloproteinases (TIMP)
|6.||Peptide Hydrolases (Proteases)